µÏÍþ¹ú¼Ê

  • µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

    ¼ò ¤™
    • ¼ò
    • ·±
    • EN
    ¤œ
    Ïà¹ØÁ´½Ó
    • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
    ÐÂÎÅ·¢²¼
    Press Release
    Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
    2025 CSCO | µÏÍþÖƵÏÍþ¹ú¼Ê°¢ÃÀÀÖ?Я¶àÏîÑо¿³É¹ûÁÁÏà
    ·¢²¼ÈÕÆÚ£º2025/09/15
    ×ÖºÅ

    2025Äê9ÔÂ10-14ÈÕ£¬ÓÉÖйúÁÙ´²Ö×Áöѧ»á£¨CSCO£©Óë±±¾©Ï£Ë¹¿ÆÁÙ´²Ö×ÁöѧÑо¿»ù½ð»áÁªºÏÖ÷°ìµÄµÚ28½ìCSCOѧÊõÄê»áÔÚɽ¶«¼ÃÄÏÕÙ¿ª¡£×÷ΪÖйúÖ×Áöѧ½ç¹æ¸ñ×î¸ß¡¢¹æÄ£×î´óµÄÄê¶ÈѧÊõÊ¢»á£¬±¾½ìÄê»áÒÔΪ¡°¹æ·¶ÕïÁÆ£¬´´ÐÂÒýÁ족ΪÖ÷Ì⣬ÎüÒýÁËÈ«¹úÍòÃûÖ×Áöר¼Ò²ÎÓë¡£×÷ΪÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬µÏÍþÖƵÏÍþ¹ú¼ÊÔÚ±¾´Î´ó»áÖÐչʾ°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáƬ£©µÄ¶àÏîÑо¿³É¹û¡£


    ´´ÐµÏÍþ¹ú¼ÊÎïÁÙ´²Ñо¿Êý¾Ýר³¡-¿ÚÍ·±¨¸æ


    Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA EGFR mutated NSCLC with High risk (APPOINT) 

    °¢ÃÀÌæÄáÓÃÓÚ¿ÉÇгýIAÆÚ°é¸ßΣ²¡ÀíÒòËØEGFRÍ»±ä·ÇСϸ°û·Î°©¸¨ÖúÖÎÁƵÄÇ°Õ°ÐÔÁÙ´²¶ÔÕÕÑо¿ 

    ͨѶ×÷Õߣºº«±¦»Ý £¨ÉϺ£½»Í¨´óѧ¸½ÊôÐØ¿ÆÒ½Ôº£©


    ´´ÐµÏÍþ¹ú¼ÊÎïÁÙ´²Ñо¿Êý¾Ýר³¡-±Ú±¨


    Aumolertinib for Treatment-Na?ve EGFR-Mutant NSCLC Patients with Brain Metastases:Updated Efficacy Data From the ARTISTRY 

    °¢ÃÀÌæÄáÖÎÁƳõÖΰéÓÐÄÔתÒƵÄEGFRÍ»±ä·ÇСϸ°û·Î°©»¼ÕߣºARTISTRYÑо¿ÁÆЧÊý¾Ý¸üР

    ͨѶ×÷ÕߣºÍõ»Û¾ê£¨ºÓÄÏÊ¡Ö×ÁöÒ½Ôº£© 

    Aumolertinib plus Anlotinib in Advanced EGFR-mutant NSCLC with TP53 Co-Mutation£ºa single-arm,phase ¢ò study 

    °¢ÃÀÌæÄáÁªºÏ°²ÂÞÌæÄáÖÎÁÆTP53¹²Í»±äÍíÆÚEGFRÍ»±ä·ÇСϸ°û·Î°©£ºÒ»Ïîµ¥±Û¢òÆÚÑо¿ 

    ͨѶ×÷Õߣº½ªÕ½Ê¤£¨Ìì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº£©


    CSCO-µÏÍþÖƵÏÍþ¹ú¼ÊרÌâ»á

    9ÔÂ11ÈÕ£¬¡¸È«³ÌÊØ»¤£¬È«Ãæ׿Խ¡¹CSCO-µÏÍþÖƵÏÍþ¹ú¼ÊרÌâ»áͬ²½¾ÙÐУ¬È«¹úÔ¼350λ·Î°©×¨¼ÒÓë»á£¬Î§ÈÆÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÄÔתÒƵÄÕïÁÆÏÖ×´ºÍδÀ´¡¢ÔçÆÚEGFRÍ»±äÊõºó¸¨ÖúÖÎÁÆÓÅÑ¡µÈÈÈÃÅ»°Ìâ½øÐÐÉîÈëÑÐÌÖ¡£

    NSCLC×ÛºÏÖÎÁƼ°ADCר³¡


    9ÔÂ12ÈÕ£¬CSCO NSCLC×ÛºÏÖÎÁƼ°ADCר³¡»áÒéÈçÆÚ¾ÙÐУ¬»áÒéΧÈÆADCÏà¹ØµÏÍþ¹ú¼ÊÎïµÄÑо¿½øÕ¹ÒÔ¼°¢óÆڷΰ©×ÛºÏÕïÁƽøÐÐѧÊõÑÐÌÖ¡£À´×ÔÉϺ£ÊзοÆÒ½ÔºµÄÈÎʤÏé½ÌÊÚ×öÁËÌâΪ¡¶ÄÚ¿ÆÊӽǵľ«×¼ÖÎÁÆʱ´ú¢óÆÚNSCLCÖÎÁÆÑ¡Ôñ¡·µÄ·ÖÏí£¬½éÉÜÁË°¢ÃÀÌæÄáARTSºÍPOLESTARÑо¿µÄ¹Ø¼üÐÅÏ¢£¬²ûÊöÁË°¢ÃÀÌæÄáÔÚÊõºó¸¨ÖúÖÎÁƺ͢óÆÚ²»¿ÉÇÐNSCLCÖÎÁÆÁìÓòµÄÓÅÑ¡µØλ¡£

    ýÌåר·Ã


    ÔÚ9ÔÂ11-12ÈÕ¾ÙÐеÄýÌåר·Ã»·½ÚÖУ¬¶àλר¼Ò·Ö±ð¾Í°¢ÃÀÌæÄáµÄÏà¹ØÑо¿½øÐвûÊÍ£¬°üÀ¨ÔÚNSCLCÄÔתÒƵ¥µÏÍþ¹ú¼Ê¡¢¼ÓÁ¿ºÍÁªºÏÖÎÁÆÖеÄÖÎÁÆÓÅÊÆ£»´ËÍ⣬°¢ÃÀÌæÄáÔÚÖÎÁÆÔçÆÚNSCLCµÄARTSÑо¿ÖÐÕ¹ÏÖ³öÓÅÒìÁÆЧ£º°¢ÃÀÌæÄá×éµÄ2ÄêDFSÂÊ´ï90.2%£¬½µµÍ¼²²¡¸´·¢·çÏÕ83%£¬Í¬Ê±°²È«ÐÔ¸ü¼Ñ£¬¿É×÷ΪEGFRÍ»±äNSCLCÊõºó¸¨ÖúÖÎÁÆÓÅÑ¡¡£

    ×÷ΪÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬µÏÍþÖƵÏÍþ¹ú¼Ê½«³ÖÐøÉî¸û·Î°©µÈÖÎÁÆÁìÓò£¬¼Ó¿ìÍƽø´´ÐµÏÍþ¹ú¼ÊÎïµÄÑз¢Éú²ú£¬Å¬Á¦ÎªÎÒ¹úÄËÖÁÈ«ÇòÏà¹Ø»¼ÕßÌṩÓÅÖʸßЧµÄÖÎÁÆÑ¡Ôñ£¬Âú×ã¸ü¶àÁÙ´²Î´¾¹Ö®Ðè¡£


    ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

    µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÔÚÖйú²úÉúÏúÊÛÊÕÈëµÄ´´ÐµÏÍþ¹ú¼Ê¹²7¿î£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£

    ÃâÔðÉùÃ÷

    ±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

    Ç°Õ°ÐÔ˵Ã÷

    ±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£




    ¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿